{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:19:03Z","timestamp":1777515543907,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.jaad.2005.05.039","type":"journal-article","created":{"date-parts":[[2005,12,29]],"date-time":"2005-12-29T07:13:10Z","timestamp":1135840390000},"page":"160-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Etanercept and demyelinating disease in a patient with psoriasis"],"prefix":"10.1016","volume":"54","author":[{"given":"Sean A.","family":"Sukal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmi","family":"Nadiminti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard D.","family":"Granstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2005.05.039_bib1","unstructured":"Enbrel [package insert]. Thousand Oaks, CA: Immunex; 2005."},{"key":"10.1016\/j.jaad.2005.05.039_bib2","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2005.05.039_bib3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2005.05.039_bib4","first-page":"270","article-title":"Etanercept for the treatment of psoriasis: combination therapy with other modalities","volume":"3","author":"Strober","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2005.05.039_bib5","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/archderm.140.3.366","article-title":"Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab","volume":"140","author":"Strober","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2005.05.039_bib6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.det.2003.12.002","article-title":"The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety","volume":"22","author":"Yamauchi","year":"2004","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2005.05.039_bib7","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1084\/jem.170.2.607","article-title":"Tumor necrosis factor identified in multiple sclerosis brain","volume":"170","author":"Hofman","year":"1989","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2005.05.039_bib8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1056\/NEJM199108153250704","article-title":"Association between tumor necrosis factor-alpha and disease and disease progression in patients with multiple sclerosis","volume":"325","author":"Sharief","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2005.05.039_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0165-5728(91)90073-G","article-title":"Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis","volume":"32","author":"Maimone","year":"1991","journal-title":"J Neuroimmunol"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2005.05.039_bib10","doi-asserted-by":"crossref","first-page":"I121","DOI":"10.1136\/ard.58.2008.i121","article-title":"The role of TNF and lymphotoxin in demyelinating disease","volume":"58","author":"Lock","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2005.05.039_bib11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ana.410230405","article-title":"Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro","volume":"23","author":"Selmaj","year":"1988","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaad.2005.05.039_bib12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4049\/jimmunol.144.1.129","article-title":"Proliferation of astrocytes in vitro in response to cytokine: a primary role for tumor necrosis factor","volume":"144","author":"Selmaj","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2005.05.039_bib13","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2005.05.039_bib14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/84603","article-title":"Genetic models for CNS inflammation","volume":"7","author":"Owens","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2005.05.039_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0733-8619(18)30061-6","article-title":"The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis","volume":"13","author":"Owens","year":"1995","journal-title":"Neurol Clin"},{"key":"10.1016\/j.jaad.2005.05.039_bib16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0165-5728(91)90125-Q","article-title":"Human tumor necrosis factor-alpha augments experimental allergic encephalomyelitis in rats","volume":"34","author":"Kuroda","year":"1991","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jaad.2005.05.039_bib17","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1084\/jem.172.4.1193","article-title":"An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis","volume":"172","author":"Ruddle","year":"1990","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2005.05.039_bib18","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/ana.410300510","article-title":"Anti-tumor necrosis factor abrogates autoimmune demyelination","volume":"30","author":"Selmaj","year":"1991","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaad.2005.05.039_bib19","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/eji.1830240916","article-title":"Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins","volume":"24","author":"Baker","year":"1994","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaad.2005.05.039_bib20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0165-5728(96)00183-X","article-title":"TNF-alpha receptor fusion protein prevents experimental autoimmune encephalomyelitis and demyelination in Lewis rats: an overview","volume":"72","author":"Klinkert","year":"1997","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jaad.2005.05.039_bib21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept multiple sclerosis study group and The University of British Columbia MS\/MRI Analysis Group","volume":"53","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jaad.2005.05.039_bib22","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2","volume":"47","author":"van Oosten","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.jaad.2005.05.039_bib23","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/eji.1830270416","article-title":"Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage\/microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factor-alpha in the central nervous system","volume":"27","author":"Taupin","year":"1997","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaad.2005.05.039_bib24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0165-5728(96)00184-1","article-title":"TNF-alpha transgenic and knockout models of CNS inflammation and degeneration","volume":"72","author":"Probert","year":"1997","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jaad.2005.05.039_bib25","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0002-9440(10)65620-9","article-title":"Late-onset chronic inflammatory encephalopathy in immune-competent and severe combined immune-deficient (SCID) mice with astrocyte-targeted expression of tumor necrosis factor","volume":"153","author":"Stalder","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaad.2005.05.039_bib26","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nm0796-788","article-title":"Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors","volume":"2","author":"Bruce","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2005.05.039_bib27","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0002-9440(10)65622-2","article-title":"Oligodendrocyte apoptosis and primary demyelination induced by local TNF\/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy","volume":"153","author":"Akassoglou","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaad.2005.05.039_bib28","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/(SICI)1521-4141(199902)29:02<626::AID-IMMU626>3.0.CO;2-A","article-title":"Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1","volume":"29","author":"Eugster","year":"1999","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaad.2005.05.039_bib29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0167-5699(99)01573-X","article-title":"Tumor necrosis factor: a master-regulator of leukocyte movement","volume":"21","author":"Sedgwick","year":"2000","journal-title":"Immunol Today"},{"key":"10.1016\/j.jaad.2005.05.039_bib30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nm0198-078","article-title":"TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination","volume":"4","author":"Liu","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2005.05.039_bib31","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1084\/jem.188.7.1343","article-title":"A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin a, or the p55TNF-R","volume":"188","author":"Douni","year":"1998","journal-title":"J Exp Med"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2005.05.039_bib32","first-page":"132","article-title":"The function of tumor necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease","volume":"59","author":"Kollias","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2005.05.039_bib33","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/ana.410380210","article-title":"Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging","volume":"38","author":"Hartung","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaad.2005.05.039_bib34","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6","article-title":"Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?","volume":"44","author":"Robinson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2005.05.039_bib35","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0923-2494(97)87239-2","article-title":"The role of TNF and related cytokines in the development and function of the autoreactive T-cell repertoire","volume":"148","author":"Cope","year":"1997","journal-title":"Res Immunol"},{"key":"10.1016\/j.jaad.2005.05.039_bib36","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0952-7915(99)00033-3","article-title":"Rheumatoid arthritis and its animal models: the role of TNF- and the possible absence of specific immune reactions","volume":"11","author":"Klareskog","year":"1999","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaad.2005.05.039_bib37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-065X.1999.tb01302.x","article-title":"Tumor necrosis factor-alpha and the progression of diabetes in non-obese diabetic mice","volume":"169","author":"Green","year":"1999","journal-title":"Immunol Rev"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2005.05.039_bib38","first-page":"149","article-title":"Tumor necrosis factor and other cytokines in murine lupus","volume":"58","author":"Theofilopoulos","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2005.05.039_bib39","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1002\/art.10488","article-title":"Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al","volume":"46","author":"Cisternas","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2005.05.039_bib40","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0404.1996.tb00004.x","article-title":"Multiple sclerosis and chronic inflammatory disease: a case-control study","volume":"93","author":"Midgard","year":"1996","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.jaad.2005.05.039_bib41","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1034\/j.1600-0404.2003.00158.x","article-title":"High frequency of psoriasis in relatives is associated with early onset in an Italian multiple sclerosis cohort","volume":"108","author":"Annunziata","year":"2003","journal-title":"Acta Neurol Scand"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962205017159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962205017159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T21:40:23Z","timestamp":1759268423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962205017159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["S0190962205017159"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2005.05.039","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Etanercept and demyelinating disease in a patient with psoriasis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2005.05.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}